Aimee Ginsburg, PharmD, BCPS

Letters to the Editor

Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars

10/20/2021

Leslie Busby, MD

Kaci Dominguez, PharmD

Josh Howell, PharmD, BCOP

Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.

Aimee Ginsburg, PharmD, BCPS,...

10/20/2021

Journal of Clinical Pathways

From the Field

Update on the Evolution of The US Oncology Network’s Clinical Pathways Program

11/18/2020

Aimee Ginsburg, PharmD, BCPS

Marcus Neubauer, MD

Lalan Wilfong, MD

Abstract: The National Comprehensive Cancer Network (NCCN) Guidelines are seen as the most comprehensive and most frequently updated cancer clinical practice guidelines available. Clinical pathways have a narrower...

...

11/18/2020

Journal of Clinical Pathways